About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ACRX
- Previous Close: $3.10
- 50 Day Moving Average: $2.82
- 200 Day Moving Average: $3.12
- 52-Week Range: $2.40 - $4.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.82
- P/E Growth: 0.00
- Market Cap: $140.53M
- Outstanding Shares: 45,333,000
- Beta: 2.63
- Net Margins: -347.94%
- Return on Equity: -232.39%
- Return on Assets: -36.36%
Companies Related to AcelRx Pharmaceuticals:
- Debt-to-Equity Ratio: 3.71%
- Current Ratio: 6.24%
- Quick Ratio: 6.15%
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
Where is AcelRx Pharmaceuticals' stock going? Where will AcelRx Pharmaceuticals' stock price be in 2017?
8 analysts have issued twelve-month target prices for AcelRx Pharmaceuticals' stock. Their predictions range from $6.00 to $15.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $8.75 in the next year.
When will AcelRx Pharmaceuticals announce their earnings?
AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about AcelRx Pharmaceuticals stock?
Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (2/7/2017)
Cowen and Company analysts commented, "AcelRx announced the advancement of ARX-04 into a multi-dose expansion phase of." (3/14/2016)
Who owns AcelRx Pharmaceuticals stock?
AcelRx Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (11.93%), Palo Alto Investors LLC (2.28%), State Street Corp (1.08%), Oxford Asset Management (0.23%) and GRT Capital Partners L.L.C. (0.11%). Company insiders that own AcelRx Pharmaceuticals stock include Howard B Rosen, Mark G Edwards and Perceptive Advisors Llc.
Who sold AcelRx Pharmaceuticals stock? Who is selling AcelRx Pharmaceuticals stock?
AcelRx Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC and GRT Capital Partners L.L.C..
Who bought AcelRx Pharmaceuticals stock? Who is buying AcelRx Pharmaceuticals stock?
AcelRx Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Oxford Asset Management and State Street Corp. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Howard B Rosen and Mark G Edwards.
How do I buy AcelRx Pharmaceuticals stock?
Shares of AcelRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of AcelRx Pharmaceuticals stock cost?
One share of AcelRx Pharmaceuticals stock can currently be purchased for approximately $3.10.